=== Intervention Extract 1 (Treatment) ===
SEOM clinical guidelines for the treatment of non‑small cell lung
cancer (2018)
M. Majem1 · O. Juan2 · A. Insa3 · N. Reguart4 · J. M. Trigo5 · E. Carcereny6 · R. García‑Campelo7 · Y. García8 ·
M. Guirado9 · M. Provencio10
Received: 22 October 2018 / Accepted: 29 October 2018 / Published online: 17 November 2018
© The Author(s) 2018 Non-smal

=== Intervention Extract 2 (Treatment) ===
nts like immunotherapy, as well as deeper
molecular knowledge; so, more options can be offered to patients with driver mutations. Groups with specific treatments
account for around 25% and demonstrate significant increases in overall survival, and in some subgroups, it is important
to evaluate each treatment alternative in accordance with scientific evidence, and even more so with immunotherapy. New
treatments similarly mean that we must reconsider what should be done in oligometastatic disease where local treatment
attains greater value.
Keywords NSCLC · Chemotherapy · Immunotherapy · Targeted therapi

=== Intervention Extract 3 (Treatment) ===
increases in overall survival, and in some subgroups, it is important
to evaluate each treatment alternative in accordance with scientific evidence, and even more so with immunotherapy. New
treatments similarly mean that we must reconsider what should be done in oligometastatic disease where local treatment
attains greater value.
Keywords NSCLC · Chemotherapy · Immunotherapy · Targeted therapies · Radiotherapy
* M. Majem 2 Medical Oncology Department, Hospital Universitari i
mmajem@santpau.cat Politècnic La Fe, Valencia, Spain
O. Juan 3 Medical Oncology Department, Hospital Clínico
ojjuanv@seom.org Un

=== Intervention Extract 4 (Treatment) ===
tion.
dence and grades of recommendation. • Bronchoscopy.
• Chest and upper abdomen (including liver and adrenal
Diagnosis glands) computerized tomography (CT).
• Brain CT or magnetic resonance imaging (MRI) is rec-
Diagnosis: pathology and molecular testing ommended for patients undergoing radical treatment,
in patients with EGFR mutation or ALK translocation
The pathological diagnosis of non-small cell lung cancer or if there are neurological symptoms in the physical
(NSCLC) should be made according to the World Health examination.
Organization (WHO) classification [1]. The International • Bone scan

=== Intervention Extract 5 (Treatment) ===
WHO) classification [1]. The International • Bone scan is recommended if there is bone pain, high
Association for the Study of Lung Cancer (IASLC) provided serum calcium or high alkaline phosphatase.
adenocarcinoma classification as well as key recommenda- In patients undergoing potentially radical treatment,
tions for the management of small biopsies and cytology [2]. additional recommendations should be considered:
For therapeutic implications, specific subtyping of NSCLC is • Whole-body FDG-positron emission tomography
strongly recommended whenever possible. Limited diagnostic (PET–CT).
workup is al

=== Intervention Extract 6 (Treatment) ===
NSCLC should, at baseline,
have their tissue assessed for programmed cell death 1 ligand During the 16th World Congress of Lung Cancer, the
(PD-L1) expression by IHC test for selecting patients for anti- International Association for the Study of Lung Cancer
programmed death 1 (PD-1) or anti-PD-L1 treatment [8]. (IASLC) proposed the TNM 8th edition that was accepted
by the Union for International Cancer Control (UICC) and
Disease staging the American Joint Committee on Cancer (AJCC) [9]. The
TNM 8th edition is effective since January 2017 (Table 1).
In NSCLC, the following staging work-up is highly Th

=== Intervention Extract 7 (Treatment) ===
resection with nega-
tive margins is suggested over lobectomy (I,B).
• Reresection is recommended for patients with positive
margins in resected stage I–II NSCLC patients. If it is not
possible, postoperative radiotherapy may be considered
Adjuvant therapy
Overall survival (OS) benefit of adjuvant treatment is limited
to cisplatin-based chemotherapy in completely resected fit
stage II–III patients [13].
• Four cycles of cisplatin-based chemotherapy following
complete resection in stage II NSCLC patients remain
the standard of care in adjuvant setting, offering a 5% OS
benefit [13] (I,A).
1b
• Stage I

=== Intervention Extract 8 (Treatment) ===
15 randomized trials showed
nt a significant benefit of preoperative chemotherapy on OS
or (representing an absolute survival improvement of 5% at
5 years [16]. Although neoadjuvant chemotherapy has simi-
on lar impact on OS than adjuvant chemotherapy, more conclu-
a- sive evidence favors adjuvant treatment (I,B).
Stereotactic ablative radiotherapy (SART)
my
ed
SART is recommended for medically inoperable NSCLC
i-
patients with node negative tumors ≤5 cm (2C). Several non-
er
randomized studies suggest that SART might be a suitable
u-
option for operable patients older than 75 years [17] (II,C).
ts
ph

=== Intervention Extract 9 (Treatment) ===
ng [18]. Stage III NSCLC is a heterogeneous and complex disease Unresectable LA-NSCLC includes stage IIIA N2 (bulky
that has been classified into different subgroups: resectable, and/or multiple nodal involvement), stage IIIB and IIIC.
potentially resectable and unresectable locally advanced
NSCLC. Treatment decision should be taken by an experi- • Concurrent chemoradiotherapy is the treatment of choice
enced multidisciplinary team (Fig. 1). for medically fit patients (I,A). Several randomized clini-
cal trials and a meta-analysis have shown a higher 5-year
Resectable and potentially resectable NSCLC s

=== Intervention Extract 10 (Treatment) ===
ncludes stage IIIA N2 (bulky
that has been classified into different subgroups: resectable, and/or multiple nodal involvement), stage IIIB and IIIC.
potentially resectable and unresectable locally advanced
NSCLC. Treatment decision should be taken by an experi- • Concurrent chemoradiotherapy is the treatment of choice
enced multidisciplinary team (Fig. 1). for medically fit patients (I,A). Several randomized clini-
cal trials and a meta-analysis have shown a higher 5-year
Resectable and potentially resectable NSCLC survival rates favoring this strategy over sequential
approaches [24].
• In patients wit

=== Intervention Extract 11 (Treatment) ===
analysis, and it is usu- 30–33 fractions over 6–7 weeks. Higher doses are not
ally administered after adjuvant chemotherapy (II,A). recommended outside of clinical trials [25].
• In patients with potentially resectable disease, the opti- • If concurrent chemoradiotherapy is not feasible due to
mal treatment strategy remains unclear. Several phase poor performance status, comorbidities, and/or unfit
III trials and a meta-analysis showed that induction ther- patients, a sequential approach is a reasonable option
apy followed by surgery might be better than surgery [26].
alone [20]. Surgery has been comp

=== Intervention Extract 12 (Treatment) ===
nial irradiation in
in patients with tumor response after induction chemo- stage III (II,A).
therapy, without differences in overall survival [21]. Sur- • In patients with no progressive disease after concurrent
gery was also compared to radiotherapy after induction chemoradiotherapy, consolidation treatment with Dur-
chemoradiotherapy in the Lung Intergroup Trial 0139 valumab for 1 year has shown to improve progression-
showing better progression-free survival in the surgery free survival (PFS) and OS (I,A) [27–29]. The European
arm, with no differences in OS except in the unplanned Medical Agency has

=== Intervention Extract 13 (Treatment) ===
men has not sion ≥ 1% based on an unplanned post hoc analysis.
been established in randomized trials, although cisplatin-
based chemotherapy is recommended.
• In case of superior sulcus (Pancoast) tumors, concur-
rent chemoradiation followed by surgery is the preferred
option [23] (Table 2).
Fig. 1 Treatment algorithm for TreatmentAlgorithmfor StageIII
Stage III
R0resectedStageIII AdjuvantPla(cid:26)numbased
CT+/-PORT(I,A-II,A)
Poten(cid:26)allyResectable CTorCT/RTfollowedby
StageIII: surgery(I,A)
T1-3N2
T4N0-1 Defini(cid:26)veCT/RT(I,A)
PS0-1,nocomorbidity, Concurrent NoPD Durvalumab
goodpulmonaryfunc

=== Intervention Extract 14 (Treatment) ===
edition
Patients should be evaluated in a multidisciplinary tumor board
Lobectomy or anatomic pulmonary resection plus systematic media
nal lymph node dissection
SART
Recommended in stage II
Not recommended in stage I 7th TNM edition (except T > 4 cm)
Not indicated in completely resected stage I–II
Treatment decision should be taken by an experienced multidisciplin
team
Adjuvant chemotherapy (four cycles of adjuvant cisplatin-based che
therapy) ± PORT
Resection followed by adjuvant chemotherapy
Induction chemotherapy or chemoradiotherapy followed by surgery
Medically fit: concurrent chemoradiotherapy w

=== Intervention Extract 15 (Treatment) ===
motherapy (four cycles of adjuvant cisplatin-based che
therapy) ± PORT
Resection followed by adjuvant chemotherapy
Induction chemotherapy or chemoradiotherapy followed by surgery
Medically fit: concurrent chemoradiotherapy with cisplatin-based
chemotherapy
Sequential chemoradiotherapy if concurrent treatment is not feasible
PCI is not indicated
Durvalumab if no progressive disease after concurrent chemoradio-
therapy
Pembrolizumab
Note: Combination of immunotherapy plus standard chemotherapy
be considered
Platinum-based chemotherapy based on tumor histology:
Platinum-based doublets (4, up to 6 cycles)

=== Intervention Extract 16 (Treatment) ===
+/-Nintedanib P D e o m ce e t t a r x e e x l e + d N (n in o t n e - d S a C n C i ) b(non-SCC)
line Pemetrexed(ifnotpreviouslygiven) Docetaxel
CT, chemotherapy; SCC, squamous; BSC, best suppor(cid:14)ve care
(*) combina(cid:14)on of immunotherapy + CT may be considered#
# Not EMA approved
Fig. 2 Treatment algorithm for Stage IV with no targetable alterations
of life (QoL) compared to supportive care, single-agent • The expected toxicity profile should contribute to the
cisplatin or other monotherapy [31–34]. selection of the chemotherapy regimen. The nab-pacli-
• Meta-analyses have shown higher resp

=== Intervention Extract 17 (Treatment) ===
to platinum-based chemotherapy chemotherapy alone, regardless of PD-L1 expression. It
regardless of the PD-L1 status [37–41] (I,A-I,B). is important to underline that these combinations were
• Cisplatin-based combinations and some modalities of not approved by the European Medical Agency when this
treatment will be selected based on tumor histology: guideline was submitted. • For PS 0–1 SCC patients, without major comorbidities • Any platinum-based doublets with a third-genera-
and with low (TPS < 50%) or unknown PD-L1, platinum- tion agent can be used in non-SCC patients with low
based doublets with

=== Intervention Extract 18 (Treatment) ===
mmended
shown improvement in OS in two randomized clinical for those patients with contraindications to immunother-
trials and, therefore, it can be offered to patients with apy or nintedanib combination therapy (non-SCC) [56,
advanced PS 0–1 non-SCC and no contraindications for 57].
antiangiogenic treatment [6, 48] (I,A). • In patients who have received an immune checkpoint
• Maintenance therapy can be considered in those PS 0–1 inhibitor as first-line therapy, platinum doublets are rec-
patients with at least stable disease and who have recov- ommended (I,B).
ered from residual toxicity after first-l

=== Intervention Extract 19 (Treatment) ===
to ascertain the true biological status [58].
plus chemotherapy) in non-SCC resulted in significantly
longer OS ± PFS than chemotherapy alone, regardless of • For those elderly fit patients with PS 0–1 and adequate
PD-L1 expression [37, 39, 41]. It is important to under- organ function, first-line treatment decision should be
line that pembrolizumab with pemetrexed and platinum- based according to histology and PD-L1 expression lev-
based chemotherapy was the only combination approved els [59] (I,B). Single agent chemotherapy (vinorelbine,
by the European Medical Agency when this guideline gemcitabine

=== Intervention Extract 20 (Treatment) ===
erapy, or palliative therapy alone may be
Patients clinically or radiologically progressing after first- used for PS 2 patients. In the first-line setting, platinum-
line therapy, with a PS 0–1 and appropriate PS 2, should be based doublets (preferably carboplatin) have superior
offered second-line treatment (I,A). Second-line treatment efficacy to monotherapy, despite higher toxicity rates
should be individualized and treatment duration should be [62, 63] (II,A).
subject to tolerability and clinical benefit. • Unfit patients with PS 3–4 should not receive active treat-
ment regardless of age because n

=== Intervention Extract 21 (Treatment) ===
alone may be
Patients clinically or radiologically progressing after first- used for PS 2 patients. In the first-line setting, platinum-
line therapy, with a PS 0–1 and appropriate PS 2, should be based doublets (preferably carboplatin) have superior
offered second-line treatment (I,A). Second-line treatment efficacy to monotherapy, despite higher toxicity rates
should be individualized and treatment duration should be [62, 63] (II,A).
subject to tolerability and clinical benefit. • Unfit patients with PS 3–4 should not receive active treat-
ment regardless of age because no benefit has been dem-
• In

=== Intervention Extract 22 (Treatment) ===
ents. In the first-line setting, platinum-
line therapy, with a PS 0–1 and appropriate PS 2, should be based doublets (preferably carboplatin) have superior
offered second-line treatment (I,A). Second-line treatment efficacy to monotherapy, despite higher toxicity rates
should be individualized and treatment duration should be [62, 63] (II,A).
subject to tolerability and clinical benefit. • Unfit patients with PS 3–4 should not receive active treat-
ment regardless of age because no benefit has been dem-
• In patients with metastatic non-SCC and SCC who have onstrated. Supportive care is recommended (I

=== Intervention Extract 23 (Treatment) ===
setting
• Nintedanib added to docetaxel has demonstrated a sig-
nificant OS benefit as compared with docetaxel alone • EGFR TKIs (gefitinib, erlotinib, afatinib) have shown
in previously treated stage IV, PS 0–1 adenocarcinoma, superior PFS, RR, toxicity profile and QoL for EGFR
TKIs as first-line treatment compared with platinum- ALK transloca(cid:31)on ROS transloca(cid:31)on EGFR muta(cid:31)on BRAFV600Emuta(cid:31)on
Alec(cid:28)nib (I,A) Gefi(cid:28)nib(I,A), Afa(cid:28)nib(I,A) Dabrafenib plus
Briga(cid:28)nib(I,B)# Crizo(cid:28)nib(III,A) Erlo(cid:28)nib(I,A) +/-bevacizumab Trame(cid:28)nib (II

=== Intervention Extract 24 (Treatment) ===
chemotherapy
Not EMA approved
*In pa(cid:31)ents who received crizo(cid:31)nibpreviously
**In pa(cid:31)ents who did not receive first-line osimer(cid:31)nib
& In pa(cid:31)ents with oligo-progression consider local strategies (surgery or SBRT) and con(cid:31)nue with targeted therapy (II,A)
Fig. 3 Treatment algorithm for Stage IV with known targetable drivers
based doublets (I,A) [64, 65]. Only a prespecified suba- After EGFR TKI progression
nalysis showed a significant improvement in OS favoring
afatinib in patients with Del19 mutations [65]. • Patients might benefit of continuation with the EGFR TKI

=== Intervention Extract 25 (Treatment) ===
FR TKIs [76]. Osimertinib has demonstrated greater
osimertinib (I,A) and dacomitinib (I,A) [66–68], to date efficacy over platinum-based chemotherapy (I,A) [77].
only dacomitinib has shown a significant OS advantage • For patients with systemic symptomatic progression
(I,A) [69]. However, grade 3–4 treatment-related adverse in whom T790 M cannot be detected or who have pro-
events were significantly higher with dacomitinib. OS gressed to osimertinib, platinum-based chemotherapy
data from the FLAURA trial comparing osimertinib ver- remains the standard of care (II,A). The combination of
sus standard of

=== Intervention Extract 26 (Treatment) ===
t-line setting demonstrating a sig- ALK translocation
nificant increase in PFS but only a slight trend of OS
improvement with the combination [71–73] (I,B). First‑line setting
• Combination of pemetrexed-carboplatin and gefitinib has
demonstrated a significant increase in PFS and OS in • First-line treatment with ALK TKIs is the preferred
japanese population [74] (I,B). treatment (I,A). Crizotinib and ceritinib have shown a
significant statistical improvement in terms of PFS and ROS‑1 and other rare targetable genetic alterations
RR compared with chemotherapy in randomized phase
III trials (I,A) [79, 8

=== Intervention Extract 27 (Treatment) ===
n PFS but only a slight trend of OS
improvement with the combination [71–73] (I,B). First‑line setting
• Combination of pemetrexed-carboplatin and gefitinib has
demonstrated a significant increase in PFS and OS in • First-line treatment with ALK TKIs is the preferred
japanese population [74] (I,B). treatment (I,A). Crizotinib and ceritinib have shown a
significant statistical improvement in terms of PFS and ROS‑1 and other rare targetable genetic alterations
RR compared with chemotherapy in randomized phase
III trials (I,A) [79, 80]. • Crizotinib is indicated for the treatment of ROS-1-pos-
• Alectinib

=== Intervention Extract 28 (Treatment) ===
se population [74] (I,B). treatment (I,A). Crizotinib and ceritinib have shown a
significant statistical improvement in terms of PFS and ROS‑1 and other rare targetable genetic alterations
RR compared with chemotherapy in randomized phase
III trials (I,A) [79, 80]. • Crizotinib is indicated for the treatment of ROS-1-pos-
• Alectinib (I,A) and brigatinib (I,B) have shown a signifi- itive advanced NSCLC based on the results of a single-
cant improvement in PFS versus crizotinib and, therefore, arm trial in 50 patients [90] (III,A).
are the preferred first-line options. Grade 3–5 adverse • Dabrafenib–Tra

=== Intervention Extract 29 (Treatment) ===
,A) and brigatinib (I,B) have shown a signifi- itive advanced NSCLC based on the results of a single-
cant improvement in PFS versus crizotinib and, therefore, arm trial in 50 patients [90] (III,A).
are the preferred first-line options. Grade 3–5 adverse • Dabrafenib–Trametinib is indicated for the treatment
events were higher for patients treated with crizotinib of advanced NSCLC BRAFV600E mutation based on
[81, 82]. It is important to underline that brigatinib was results from non-comparative studies in pretreated or
not approved by the European Medical Agency when this naïve patients [91, 92] (II,A)

=== Intervention Extract 30 (Treatment) ===
uropean Medical Agency when this naïve patients [91, 92] (II,A).
guideline was submitted. • New investigational drugs have shown activity in
• Chemotherapy is indicated (III,B) in patients whose ALK early clinical trials targeting oncogenic drivers such
results are not available and urgent systemic treatment as crizotinib, tepotinib or capmatinib (MET amplified,
is required. Treatment plan should be reassured when M ETe14 mutation), LOXO-292 and BLU-667 (RET),
genotypic results were available. entrectinib (NRTK, ROS, ALK fusions), LOXO-101 or
• For patients who received chemotherapy in the first-line,

=== Intervention Extract 31 (Treatment) ===
submitted. • New investigational drugs have shown activity in
• Chemotherapy is indicated (III,B) in patients whose ALK early clinical trials targeting oncogenic drivers such
results are not available and urgent systemic treatment as crizotinib, tepotinib or capmatinib (MET amplified,
is required. Treatment plan should be reassured when M ETe14 mutation), LOXO-292 and BLU-667 (RET),
genotypic results were available. entrectinib (NRTK, ROS, ALK fusions), LOXO-101 or
• For patients who received chemotherapy in the first-line, larotrectinib (NRTK fusions) [93] and ado-trastuzumab
crizotinib should be rec

=== Intervention Extract 32 (Treatment) ===
or to multiple lesions in
a favorable PFS in a crizotinib-refractory ALK-positive
multiple organs. The most accepted number of metastatic
phase II trial [84–86].
lesions is up to five and, most important, these should
• Lorlatinib has shown activity in patients who have pro-
be suitable to radical treatment by local therapy: surgi-
gressed on next-generation ALK TKI (ceritinib, alectinib
cal resection, SART or both. The oligometastatic disease
or brigatinib) [87] (II,A).
comprises four different settings [94]:
• Ensartinib and entrectinib have also been demonstrated
activity in previously treated pati

=== Intervention Extract 33 (Treatment) ===
imary tumor
• For patients with systemic symptomatic progression to
are suitable to radical therapy.
ALK TKI, platinum-based chemotherapy remains the
2. Multiple metastases that are transformed into an oli-
standard of care (II,A). The combination of atezolizumab
gometastatic disease after systemic treatment due to
plus bevacizumab plus chemotherapy has demonstrated
response, and all lesions can be managed with radical
a significant PFS benefit (III,B) [50].
intent.
3. The primary tumor and most areas of metastatic disease
Brain metastases
remain controlled, but one or a limited number of metas-
tases

=== Intervention Extract 34 (Treatment) ===
to pri-
with steroids, brain-penetrable ALK TKIs may be used
mary and all metastatic sites. Two phase II studies
and local treatments may be deferred (I,B).
showed that LAT after systemic therapy increased Novartis, Tesaro, outside the submitted work. OJ reports grants from
PFS vs no further local treatment [95, 96] (I,A). Astra Zeneca and personal fees from Astra Zeneca, BMS, MSD,
ROCHE, Boehringer Ingelheim, Lilly outside the submitted work.
• Patients with actionable mutations receiving targeted
MP reports grants from BMS, Roche and personal fees from BMS,
therapies who progress on isolated site ca

=== Intervention Extract 35 (Treatment) ===
a, Lilly,
Takeda outside the submitted work; Research Funding from Pfizer,
NanoString Technology, and Institutional financial interests related to
• Smoking cessation counseling is encouraged in any stage clinical trials and patient recruitment. GC reports non-financial sup-
as it leads to superior treatment outcomes since smoking port from Millennium Pharmaceuticals, Inc., during the conduct of the
study; personal fees from ARIAD, AstraZeneca, Roche, Pfizer, BMS,
may impact on drugs’ bioavailability (II,A).
Boehringer Ingelheim, MSD outside the submitted work. YG reports
• There is not an established

=== Intervention Extract 36 (Treatment) ===
reports personal fees from
to the inherent aggressiveness of the disease, a close fol- Roche, Boehriger-ingelheim, BMS, Astra Zeneca, MerckSerono out-
side the submitted work. AI, EC, MG, have not reported any potential
low-up is advised.
conflicts of interest.
Follow up in patients after curative treatment: Ethical approval The current study has been performed in accordance
with the ethical standards laid down in the 1964 Declaration of Hel-
sinki and its later amendments.
• NSCLC patients treated with radical intent must be fol-
lowed to identify treatment-related complications, detec- Informed cons

=== Intervention Extract 37 (Treatment) ===
erest.
Follow up in patients after curative treatment: Ethical approval The current study has been performed in accordance
with the ethical standards laid down in the 1964 Declaration of Hel-
sinki and its later amendments.
• NSCLC patients treated with radical intent must be fol-
lowed to identify treatment-related complications, detec- Informed consent No informed consent was necessary for this guide-
tion of treatable relapse or occurrence of second primary line.
lung cancer (III,A).
• In patients with curative surgery, a close follow-up visit Open Access This article is distributed under the terms

=== Intervention Extract 38 (Treatment) ===
on. J Thorac Oncol.
2. Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB,
• Early palliative care is strongly recommended [98] (I,A).
Bernicker EH, et al. Updated molecular testing guideline for
• Evaluation of response is recommended every 6–12 weeks the selection of lung cancer patients for treatment with targeted
after therapy initiation, using the same baseline radio- tyrosine kinase inhibitors: guideline from the college of American
pathologists, the international association for the study of lung
graphic method. The frequency of the radiologic assess-
cancer, and the association for molecul

=== Intervention Extract 39 (Treatment) ===
ime on
targeted agents (III,B). 3. Felip E, Concha A, de Castro J, Gomez-Roman J, Garrido P, Ram-
• For patients eligible for successive lines that respond to irez J, et al. Biomarker testing in advanced non-small-cell lung
cancer: a national consensus of the spanish society of pathology
first-line treatment, it is advisable to undergo clinical and/
and the spanish society of medical oncology. Clin Transl Oncol.
or radiological evaluation 6 weeks after finishing treatment
and then every 6–12 weeks to enable second-line therapy 4. Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG,
to commence

=== Intervention Extract 40 (Treatment) ===
et al. Biomarker testing in advanced non-small-cell lung
cancer: a national consensus of the spanish society of pathology
first-line treatment, it is advisable to undergo clinical and/
and the spanish society of medical oncology. Clin Transl Oncol.
or radiological evaluation 6 weeks after finishing treatment
and then every 6–12 weeks to enable second-line therapy 4. Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG,
to commence promptly (III,B). et al. Metastatic non-small-cell lung cancer: ESMO clinical prac-
tice guidelines for diagnosis, treatment and follow-up. Ann Oncol.
2016;27(suppl 5

=== Intervention Extract 41 (Treatment) ===
ogical evaluation 6 weeks after finishing treatment
and then every 6–12 weeks to enable second-line therapy 4. Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG,
to commence promptly (III,B). et al. Metastatic non-small-cell lung cancer: ESMO clinical prac-
tice guidelines for diagnosis, treatment and follow-up. Ann Oncol.
2016;27(suppl 5):v1–27.
5. Kalemkerian GP, Narula N, Kennedy EB, Biermann WA, Don-
Compliance with ethical standards
ington J, Leighl NB, et al. Molecular testing guideline for the
selection of patients with lung cancer for treatment with targeted
Conflict of interest MM r

=== Intervention Extract 42 (Treatment) ===
al prac-
tice guidelines for diagnosis, treatment and follow-up. Ann Oncol.
2016;27(suppl 5):v1–27.
5. Kalemkerian GP, Narula N, Kennedy EB, Biermann WA, Don-
Compliance with ethical standards
ington J, Leighl NB, et al. Molecular testing guideline for the
selection of patients with lung cancer for treatment with targeted
Conflict of interest MM reports personal fees from AstraZeneca, tyrosine kinase inhibitors: American Society of Clinical Oncol-
Roche, Lilly, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, ogy endorsement of the College of American Pathozlogists/
International Association for the

=== Intervention Extract 43 (Treatment) ===
):830–8. Smit EF, Schramel F, et al. Randomized controlled trial of
35. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paes- lung cancer: a randomised, double-blind, phase 3 study. Lancet.
mans M, et al. Cisplatin- versus carboplatin-based chemotherapy 2009;374(9699):1432–40.
in first-line treatment of advanced non-small-cell lung cancer: 50. Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli
an individual patient data meta-analysis. J Natl Cancer Inst. P, et al. PARAMOUNT: final overall survival results of the phase
2007;99(11):847–57. III study of maintenance pemetrexed versus pl

=== Intervention Extract 44 (Treatment) ===
idoli
an individual patient data meta-analysis. J Natl Cancer Inst. P, et al. PARAMOUNT: final overall survival results of the phase
2007;99(11):847–57. III study of maintenance pemetrexed versus placebo immedi-
36. D’Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd ately after induction treatment with pemetrexed plus cisplatin for
FA. Platinum-based versus non-platinum-based chemotherapy in advanced nonsquamous non-small-cell lung cancer. J Clin Oncol.
advanced non-small-cell lung cancer: a meta-analysis of the pub- 2013;31(23):2895–902.
lished literature. J Clin Oncol. 2005;23(13):2926–36.

=== Intervention Extract 45 (Drug) ===
zumab
crizotinib should be recommended as second-line treat- emtansine (HER2 mutations). However, none of these
ment (I,A) [83]. Alectinib and ceritinib should also be targeted drugs have an official regulatory approval by
considered, although no specific trials have been con- EMA except the orphan drug designation of LOXO-101
ducted. in NTRK fusion tumors. • For patients who develop resistance or are intolerant
to crizotinib, ceritinib (IA), alectinib (IA) or brigatinib
The oligometastatic state consists of patients with metasta-
(IIA) can be recommended. Ceritinib and alectinib have
sis limited

=== Intervention Extract 46 (Therapy) ===
g lymph node dissection for accu
rate pathologic staging [10] (IB). For stage II patient
undergoing anatomic resection, mediastinal lymp
node dissection may provide additional survival benefi
over sampling [11] (II,B).
• A sublobar resection (anatomical segmentectomy) i
recommended over nonsurgical therapy for patient
who cannot tolerate a lobar resection due to decrease
pulmonary function or comorbid disease (I,B).
• For patients with a stage I predominantly ground glass
opacity with lesion ≤ 1 cm, sublobar resection with nega-
tive margins is suggested over lobectomy (I,B).
• Reresection is recomme

=== Intervention Extract 47 (Therapy) ===
ground glass
opacity with lesion ≤ 1 cm, sublobar resection with nega-
tive margins is suggested over lobectomy (I,B).
• Reresection is recommended for patients with positive
margins in resected stage I–II NSCLC patients. If it is not
possible, postoperative radiotherapy may be considered
Adjuvant therapy
Overall survival (OS) benefit of adjuvant treatment is limited
to cisplatin-based chemotherapy in completely resected fit
stage II–III patients [13].
• Four cycles of cisplatin-based chemotherapy following
complete resection in stage II NSCLC patients remain
the standard of care in adjuvant setting

=== Intervention Extract 48 (Therapy) ===
ed fit
stage II–III patients [13].
• Four cycles of cisplatin-based chemotherapy following
complete resection in stage II NSCLC patients remain
the standard of care in adjuvant setting, offering a 5% OS
benefit [13] (I,A).
1b
• Stage I (7th TNM edition) NSCLC patients do not ben-
efit from adjuvant therapy except those patients with
tumors > 4 cm [5, 14] (I,C).
• In elderly fit patients, adjuvant platinum-based chemo-
therapy should be considered.
• Postoperative radiotherapy (PORT) is not indicated in
C
completely resected stage I–II NSCLC patients [15] (I,A-
d,
II,A).
ve Preoperative chemotherapy h

=== Intervention Extract 49 (Therapy) ===
NSCLC patients remain
the standard of care in adjuvant setting, offering a 5% OS
benefit [13] (I,A).
1b
• Stage I (7th TNM edition) NSCLC patients do not ben-
efit from adjuvant therapy except those patients with
tumors > 4 cm [5, 14] (I,C).
• In elderly fit patients, adjuvant platinum-based chemo-
therapy should be considered.
• Postoperative radiotherapy (PORT) is not indicated in
C
completely resected stage I–II NSCLC patients [15] (I,A-
d,
II,A).
ve Preoperative chemotherapy has the potential role to reduce
tumor size, increase operability, and eliminate micrometas-
i- tases. A meta-analysis with

=== Intervention Extract 50 (Therapy) ===
patients, a sequential approach is a reasonable option
apy followed by surgery might be better than surgery [26].
alone [20]. Surgery has been compared to radiotherapy • There is no role for prophylactic cranial irradiation in
in patients with tumor response after induction chemo- stage III (II,A).
therapy, without differences in overall survival [21]. Sur- • In patients with no progressive disease after concurrent
gery was also compared to radiotherapy after induction chemoradiotherapy, consolidation treatment with Dur-
chemoradiotherapy in the Lung Intergroup Trial 0139 valumab for 1 year has shown

=== Intervention Extract 51 (Therapy) ===
pulmonaryfunc(cid:26)on CT/RT(I,A) (I,A)
UnresectableStageIII
PS2,and/orcomorbidity Sequen(cid:26)al
and/orimpairedlung CT/RT(I,A)
func(cid:26)on
Clinical and Translational O
Table 2 Summary of reco
Diagnosis
Staging
Stage I–II
Medically fit for surgery
Medically inoperable, n
Adjuvant chemotherapy
therapy)
Post operative radiother
Stage III
Completely resected
Potentially resectable
Unresectable stage III
Stage IV
Stage IV without driver m
Fist line
PD-L1 ≥ 50%
PD-L1 < 50% or unknow
Squamous cell carcinoma
Non-squamous-cell carcin
Elderly
Fit patients
Unfit or comorbidities
PS 2
PS 3–4
Oncology
omme

=== Intervention Extract 52 (Therapy) ===
lymph node dissection
SART
Recommended in stage II
Not recommended in stage I 7th TNM edition (except T > 4 cm)
Not indicated in completely resected stage I–II
Treatment decision should be taken by an experienced multidisciplin
team
Adjuvant chemotherapy (four cycles of adjuvant cisplatin-based che
therapy) ± PORT
Resection followed by adjuvant chemotherapy
Induction chemotherapy or chemoradiotherapy followed by surgery
Medically fit: concurrent chemoradiotherapy with cisplatin-based
chemotherapy
Sequential chemoradiotherapy if concurrent treatment is not feasible
PCI is not indicated
Durvalumab if n

=== Intervention Extract 53 (Therapy) ===
y
Induction chemotherapy or chemoradiotherapy followed by surgery
Medically fit: concurrent chemoradiotherapy with cisplatin-based
chemotherapy
Sequential chemoradiotherapy if concurrent treatment is not feasible
PCI is not indicated
Durvalumab if no progressive disease after concurrent chemoradio-
therapy
Pembrolizumab
Note: Combination of immunotherapy plus standard chemotherapy
be considered
Platinum-based chemotherapy based on tumor histology:
Platinum-based doublets (4, up to 6 cycles)
Immunotherapy (atezolizumab or pembrolizumab) and carboplatin p
paclitaxel or nab-placlitaxel)(#)
Platinum-base

=== Intervention Extract 54 (Therapy) ===
num doublet. if there are no contraindi
tions
Pemetrexed maintenance
Immunotherapy (atezolizumab(#) or pembrolizumab) plus standard
chemotherapy
Comprehensive geriatric assessment is highly recommended
Decision according to histology and PD-L1 expression levels
Single agent chemotherapy
Combination therapy
Single-agent therapy
Best supportive care
Best supportive care
gly
ermi-
LC
CT
is
asti-
nary
emo-
e
may
plus
atin/
ica-
Table 2 (continued)
Second line
PS 0–2
If no prior immunotherapy
If prior immunotherapy
If contraindication for immuno
If prior immunotherapy alone
If prior immunotherapy + CT
PS

=== Intervention Extract 55 (Therapy) ===
are no contraindi
tions
Pemetrexed maintenance
Immunotherapy (atezolizumab(#) or pembrolizumab) plus standard
chemotherapy
Comprehensive geriatric assessment is highly recommended
Decision according to histology and PD-L1 expression levels
Single agent chemotherapy
Combination therapy
Single-agent therapy
Best supportive care
Best supportive care
gly
ermi-
LC
CT
is
asti-
nary
emo-
e
may
plus
atin/
ica-
Table 2 (continued)
Second line
PS 0–2
If no prior immunotherapy
If prior immunotherapy
If contraindication for immuno
If prior immunotherapy alone
If prior immunotherapy + CT
PS 3–4
Stage IV with dri

=== Intervention Extract 56 (Therapy) ===
ed or
T790 M positive
T790 M negative
ALK mutation
First-line ALK TKI
Progression to crizotinib
Brain metastasis
Other genetic alterations
ROS-1
B-RAFv600
Oligometastatic disease
Follow-up
Curative intent
Surgery
SART
Advanced disease
(#) Not EMA approved
Stage IV
Stage IV without driver
First‑line therapy
• For stage IV, PS 0–1 N
mutations whose tumor
otherap
oligopr
muta
NSCL
rs expr
py
rogress
ations
LC pat
ress PD
sive dise
s (Fig.
tients w
D-L1 a
ease
withou
at level
ut driv
ls of 50
Pembrolizumab (PD-L1 ≥ 1%), nivolumab or atezolizumab
Platinum doublets
Docetaxel–nintedanib (non-SCC)
Docetaxel

=== Intervention Extract 57 (Therapy) ===
, osimertinib
Osimertinib
Continuation with the EGFR TKI
Osimertinib (if not previously given)
Platinum-based chemotherapy
Alectinib, brigatinib(#), crizotinib or ceritinib
Ceritinib, alectinib or brigatinib(#)
Alectinib, brigatinib(#) or lorlatinib(#)
Crizotinib
Dabrafenib plus trametinib
Systemic therapy and local ablative strategies
Local ablative strategies and TKI-continuation if clinical benefit is still
retained (if actionable mutation)
Smoking cessation counseling
Medical history, physical examination and spiral chest CT scan every
6–12 months for 2 years and annually thereafter
Medical histo

=== Intervention Extract 58 (Therapy) ===
he absence of contrain-
dications to use immunotherapy [30] (I,A).
• For patients with low (TPS < 50%) or unknown PD-L1
expression, chemotherapy with platinum doublets should
be considered in all stage IV PS 0–1 NSCLCs without
ver driver mutations (I,A). Data have shown that platinum
0% combination therapy increases OS and improves quality PS 0-1 PS 2 PS 3-4
PD-L1≥ 50%
PD-L1< 50%
SCC and non-SCC
1st
Single agentCT (I,B)
line SCC non-SCC Carbopla(cid:31)n-based BSC (II,B)
CT (II,A)
Pla(cid:31)num+Pemetrexed(II,A)
Pla(cid:31)num based-CT (I,A) Taxol+CBDCA+Bevacizumab(I,A) Pembrolizumab(I,A)(*)
Pla(cid:

=== Intervention Extract 59 (Therapy) ===
to a maximum of six or docetaxel-based combinations (results coming from a
cycles in selected cases [43, 44] (I,A).
meta-analysis and a preplanned subgroup analysis of a particularly in those patients progressing within 9 months
randomized phase III trial) [46, 47] (II,A). after start of first-line therapy [55] (II,B).
• Bevacizumab/paclitaxel/carboplatin combination chem- • Docetaxel, or pemetrexed have demonstrated improve-
otherapy followed by maintenance bevacizumab has ment in terms of OS and QoL (I,B) and are recommended
shown improvement in OS in two randomized clinical for those patients with

=== Intervention Extract 60 (Therapy) ===
otherapy followed by maintenance bevacizumab has ment in terms of OS and QoL (I,B) and are recommended
shown improvement in OS in two randomized clinical for those patients with contraindications to immunother-
trials and, therefore, it can be offered to patients with apy or nintedanib combination therapy (non-SCC) [56,
advanced PS 0–1 non-SCC and no contraindications for 57].
antiangiogenic treatment [6, 48] (I,A). • In patients who have received an immune checkpoint
• Maintenance therapy can be considered in those PS 0–1 inhibitor as first-line therapy, platinum doublets are rec-
patients with at

=== Intervention Extract 61 (Therapy) ===
ications to immunother-
trials and, therefore, it can be offered to patients with apy or nintedanib combination therapy (non-SCC) [56,
advanced PS 0–1 non-SCC and no contraindications for 57].
antiangiogenic treatment [6, 48] (I,A). • In patients who have received an immune checkpoint
• Maintenance therapy can be considered in those PS 0–1 inhibitor as first-line therapy, platinum doublets are rec-
patients with at least stable disease and who have recov- ommended (I,B).
ered from residual toxicity after first-line chemotherapy: • For those patients who have received first-line conven-
tional chemoth

=== Intervention Extract 62 (Therapy) ===
o patients with apy or nintedanib combination therapy (non-SCC) [56,
advanced PS 0–1 non-SCC and no contraindications for 57].
antiangiogenic treatment [6, 48] (I,A). • In patients who have received an immune checkpoint
• Maintenance therapy can be considered in those PS 0–1 inhibitor as first-line therapy, platinum doublets are rec-
patients with at least stable disease and who have recov- ommended (I,B).
ered from residual toxicity after first-line chemotherapy: • For those patients who have received first-line conven-
tional chemotherapyand immune therapy, single agent,
• Pemetrexed switch mainten

=== Intervention Extract 63 (Therapy) ===
ed in those PS 0–1 inhibitor as first-line therapy, platinum doublets are rec-
patients with at least stable disease and who have recov- ommended (I,B).
ered from residual toxicity after first-line chemotherapy: • For those patients who have received first-line conven-
tional chemotherapyand immune therapy, single agent,
• Pemetrexed switch maintenance could be considered docetaxel, pemetrexed (non-SCC) or docetaxel plus nin-
after four cycles of non-pemetrexed platinum-based tedanib (non-SCC) could be considered (IIB).
chemotherapy [49] (I,B). • There is no sufficient evidence to recommend the use o

=== Intervention Extract 64 (Therapy) ===
xed (non-SCC) or docetaxel plus nin-
after four cycles of non-pemetrexed platinum-based tedanib (non-SCC) could be considered (IIB).
chemotherapy [49] (I,B). • There is no sufficient evidence to recommend the use of
• Pemetrexed continuation maintenance should be con- cytotoxic drugs as fourth-line therapy or beyond; patients
sidered in patients having disease control after four should be considered to be included in clinical trials, and
courses of pemetrexed platinum-based chemotherapy continued best supportive care.
[50] (I,A).
Elderly and PS2
• Recently, three randomized phase III trials have show

=== Intervention Extract 65 (Therapy) ===
erapy (vinorelbine,
by the European Medical Agency when this guideline gemcitabine, docetaxel) is recommended for those with
was submitted. comorbidities or unfit patients [60] (IB).
• For patients with PS 2, chemotherapy prolongs OS
compared to best supportive care (BSC) [61] (I,B). In
Second‑line therapy
an individualized-based decision, combination therapy,
single-agent therapy, or palliative therapy alone may be
Patients clinically or radiologically progressing after first- used for PS 2 patients. In the first-line setting, platinum-
line therapy, with a PS 0–1 and appropriate PS 2, should be bas

=== Intervention Extract 66 (Therapy) ===
n this guideline gemcitabine, docetaxel) is recommended for those with
was submitted. comorbidities or unfit patients [60] (IB).
• For patients with PS 2, chemotherapy prolongs OS
compared to best supportive care (BSC) [61] (I,B). In
Second‑line therapy
an individualized-based decision, combination therapy,
single-agent therapy, or palliative therapy alone may be
Patients clinically or radiologically progressing after first- used for PS 2 patients. In the first-line setting, platinum-
line therapy, with a PS 0–1 and appropriate PS 2, should be based doublets (preferably carboplatin) have superior
off

=== Intervention Extract 67 (Therapy) ===
tabine, docetaxel) is recommended for those with
was submitted. comorbidities or unfit patients [60] (IB).
• For patients with PS 2, chemotherapy prolongs OS
compared to best supportive care (BSC) [61] (I,B). In
Second‑line therapy
an individualized-based decision, combination therapy,
single-agent therapy, or palliative therapy alone may be
Patients clinically or radiologically progressing after first- used for PS 2 patients. In the first-line setting, platinum-
line therapy, with a PS 0–1 and appropriate PS 2, should be based doublets (preferably carboplatin) have superior
offered second-line treat

=== Intervention Extract 68 (Therapy) ===
ecommended for those with
was submitted. comorbidities or unfit patients [60] (IB).
• For patients with PS 2, chemotherapy prolongs OS
compared to best supportive care (BSC) [61] (I,B). In
Second‑line therapy
an individualized-based decision, combination therapy,
single-agent therapy, or palliative therapy alone may be
Patients clinically or radiologically progressing after first- used for PS 2 patients. In the first-line setting, platinum-
line therapy, with a PS 0–1 and appropriate PS 2, should be based doublets (preferably carboplatin) have superior
offered second-line treatment (I,A). Second-line

=== Intervention Extract 69 (Therapy) ===
t supportive care (BSC) [61] (I,B). In
Second‑line therapy
an individualized-based decision, combination therapy,
single-agent therapy, or palliative therapy alone may be
Patients clinically or radiologically progressing after first- used for PS 2 patients. In the first-line setting, platinum-
line therapy, with a PS 0–1 and appropriate PS 2, should be based doublets (preferably carboplatin) have superior
offered second-line treatment (I,A). Second-line treatment efficacy to monotherapy, despite higher toxicity rates
should be individualized and treatment duration should be [62, 63] (II,A).
subject t

=== Intervention Extract 70 (Therapy) ===
Pla(cid:28)num-based chemotherapy
Not EMA approved
*In pa(cid:31)ents who received crizo(cid:31)nibpreviously
**In pa(cid:31)ents who did not receive first-line osimer(cid:31)nib
& In pa(cid:31)ents with oligo-progression consider local strategies (surgery or SBRT) and con(cid:31)nue with targeted therapy (II,A)
Fig. 3 Treatment algorithm for Stage IV with known targetable drivers
based doublets (I,A) [64, 65]. Only a prespecified suba- After EGFR TKI progression
nalysis showed a significant improvement in OS favoring
afatinib in patients with Del19 mutations [65]. • Patients might benefit of contin

=== Intervention Extract 71 (Therapy) ===
a significant PFS benefit in the subgroup
probability of experiencing a progression on central of patients with EGFR mutation (III,A) [50].
nervous system (CNS) was lower with osimertinib and • Continuation of EGFR TKI with platinum-based chemo-
provided a higher intracranial activity (II,B) [70]. therapy does not impact on PFS nor on OS [78] (I,A).
• Combinations of bevacizumab and erlotinib were also
explored in the first-line setting demonstrating a sig- ALK translocation
nificant increase in PFS but only a slight trend of OS
improvement with the combination [71–73] (I,B). First‑line setting
• Co

=== Intervention Extract 72 (Therapy) ===
ions in
a favorable PFS in a crizotinib-refractory ALK-positive
multiple organs. The most accepted number of metastatic
phase II trial [84–86].
lesions is up to five and, most important, these should
• Lorlatinib has shown activity in patients who have pro-
be suitable to radical treatment by local therapy: surgi-
gressed on next-generation ALK TKI (ceritinib, alectinib
cal resection, SART or both. The oligometastatic disease
or brigatinib) [87] (II,A).
comprises four different settings [94]:
• Ensartinib and entrectinib have also been demonstrated
activity in previously treated patients in early pha

=== Intervention Extract 73 (Therapy) ===
ib and entrectinib have also been demonstrated
activity in previously treated patients in early phase trials
1. Metastatic lesions limited in number and location at
diagnosis, all the lesions including the primary tumor
• For patients with systemic symptomatic progression to
are suitable to radical therapy.
ALK TKI, platinum-based chemotherapy remains the
2. Multiple metastases that are transformed into an oli-
standard of care (II,A). The combination of atezolizumab
gometastatic disease after systemic treatment due to
plus bevacizumab plus chemotherapy has demonstrated
response, and all lesions can

=== Intervention Extract 74 (Therapy) ===
plus chemotherapy has demonstrated
response, and all lesions can be managed with radical
a significant PFS benefit (III,B) [50].
intent.
3. The primary tumor and most areas of metastatic disease
Brain metastases
remain controlled, but one or a limited number of metas-
tases progress while systemic therapy.
• Alectinib, brigatinib and lorlatinib have showngreater 4. Oligorecurrence occurs in patients treated with cura-
activity in CNS disease. In the ALEX trial, fewer patients tive intent and metachronously present 1–5 metastastic
treated with alectinib (12%) had CNS progression than lesions suitable

=== Intervention Extract 75 (Therapy) ===
, brigatinib and lorlatinib have showngreater 4. Oligorecurrence occurs in patients treated with cura-
activity in CNS disease. In the ALEX trial, fewer patients tive intent and metachronously present 1–5 metastastic
treated with alectinib (12%) had CNS progression than lesions suitable to ablative therapy.
crizotinib (45%). In the ALTA-1 trial, intracranial RR
• Patients with oligometastatic disease at diagno-
was 78% for brigatinib versus 29% for crizotinib [82].
sis should be treated with systemic therapy and
• For asymptomatic or patients who became asymptomatic
local consolidative ablative thera

=== Intervention Extract 76 (Therapy) ===
etastastic
treated with alectinib (12%) had CNS progression than lesions suitable to ablative therapy.
crizotinib (45%). In the ALTA-1 trial, intracranial RR
• Patients with oligometastatic disease at diagno-
was 78% for brigatinib versus 29% for crizotinib [82].
sis should be treated with systemic therapy and
• For asymptomatic or patients who became asymptomatic
local consolidative ablative therapy (LAT) to pri-
with steroids, brain-penetrable ALK TKIs may be used
mary and all metastatic sites. Two phase II studies
and local treatments may be deferred (I,B).
showed that LAT after systemic therapy i

=== Intervention Extract 77 (Therapy) ===
erapy.
crizotinib (45%). In the ALTA-1 trial, intracranial RR
• Patients with oligometastatic disease at diagno-
was 78% for brigatinib versus 29% for crizotinib [82].
sis should be treated with systemic therapy and
• For asymptomatic or patients who became asymptomatic
local consolidative ablative therapy (LAT) to pri-
with steroids, brain-penetrable ALK TKIs may be used
mary and all metastatic sites. Two phase II studies
and local treatments may be deferred (I,B).
showed that LAT after systemic therapy increased Novartis, Tesaro, outside the submitted work. OJ reports grants from
PFS vs no further

=== Intervention Extract 78 (Therapy) ===
c therapy and
• For asymptomatic or patients who became asymptomatic
local consolidative ablative therapy (LAT) to pri-
with steroids, brain-penetrable ALK TKIs may be used
mary and all metastatic sites. Two phase II studies
and local treatments may be deferred (I,B).
showed that LAT after systemic therapy increased Novartis, Tesaro, outside the submitted work. OJ reports grants from
PFS vs no further local treatment [95, 96] (I,A). Astra Zeneca and personal fees from Astra Zeneca, BMS, MSD,
ROCHE, Boehringer Ingelheim, Lilly outside the submitted work.
• Patients with actionable mutations receiving

=== Intervention Extract 79 (Therapy) ===
n NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB,
• Early palliative care is strongly recommended [98] (I,A).
Bernicker EH, et al. Updated molecular testing guideline for
• Evaluation of response is recommended every 6–12 weeks the selection of lung cancer patients for treatment with targeted
after therapy initiation, using the same baseline radio- tyrosine kinase inhibitors: guideline from the college of American
pathologists, the international association for the study of lung
graphic method. The frequency of the radiologic assess-
cancer, and the association for molecular pathology. J Mol Diagn.
m

=== Intervention Extract 80 (Therapy) ===
ancer: a national consensus of the spanish society of pathology
first-line treatment, it is advisable to undergo clinical and/
and the spanish society of medical oncology. Clin Transl Oncol.
or radiological evaluation 6 weeks after finishing treatment
and then every 6–12 weeks to enable second-line therapy 4. Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG,
to commence promptly (III,B). et al. Metastatic non-small-cell lung cancer: ESMO clinical prac-
tice guidelines for diagnosis, treatment and follow-up. Ann Oncol.
2016;27(suppl 5):v1–27.
5. Kalemkerian GP, Narula N, Kennedy EB, Bierma

=== Intervention Extract 81 (Therapy) ===
ia JL, Han
with advanced non-small-cell lung cancer and Eastern coop- 76. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W,
erative oncology group performance status of 2. J Clin Oncol. et al. Analysis of tumor specimens at the time of acquired resist-
2013;31(23):2849–53. ance to EGFR-TKI therapy in 155 patients with EGFR-mutant
lung cancer: an open-label, phase 2 trial. Lancet Oncol. non-small-cell lung cancer without progression after first-line
2017;18(10):1307–16. systemic therapy: a multicentre, randomised, controlled, phase 2
92. Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, B

=== Intervention Extract 82 (Therapy) ===
l. et al. Analysis of tumor specimens at the time of acquired resist-
2013;31(23):2849–53. ance to EGFR-TKI therapy in 155 patients with EGFR-mutant
lung cancer: an open-label, phase 2 trial. Lancet Oncol. non-small-cell lung cancer without progression after first-line
2017;18(10):1307–16. systemic therapy: a multicentre, randomised, controlled, phase 2
92. Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik study. Lancet Oncol. 2016;17(12):1672–82.
CS, et al. Dabrafenib plus trametinib in patients with previously 96. Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS,
treated BRAF(V60

=== Intervention Extract 83 (Therapy) ===
etri GD, et al. Efficacy of larotrectinib in TRK fusion-positive can- et al. Clinical benefit of continuing ALK inhibition with crizotinib
cers in adults and children. New Engl J Med. 2018;378(8):731–9. beyond initial disease progression in patients with advanced ALK-
94. Juan O, Popat S. Ablative therapy for oligometastatic non-small positive NSCLC. Ann Oncol. 2014;25(2):415–22.
cell lung cancer. Clin Lung Cancer. 2017;18(6):595–606. 98. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane

=== Intervention Extract 84 (Dose) ===
n-based combinations are recommended for med-
adjuvant platinum-based chemotherapy should be given ically fit patients (usually with etoposide or vinorelbine)
(preferably cisplatin doublet) [19] (I,A). [24].
• In patients with pathological N2 NSCLC, PORT appears • Radiotherapy is usually given at a dose of 60–66 Gy in
to improve OS in non-randomized analysis, and it is usu- 30–33 fractions over 6–7 weeks. Higher doses are not
ally administered after adjuvant chemotherapy (II,A). recommended outside of clinical trials [25].
• In patients with potentially resectable disease, the opti- • If concurren

